October 16, 2025 — Leads & Copy — Owkin has launched K Pro, an AI co-pilot designed to bring advanced agentic AI to biomedical research and drug development. The platform helps pharmaceutical companies and biotechs make informed decisions, increase clinical success rates, and deliver data-driven biological insights.
K Pro is built on a decade of Owkin’s AI innovation and integrates Owkin Zero, a biological LLM. It allows users to ask complex biological questions and receive actionable answers, unifying fragmented workflows into an insight-driven research experience. Users can also securely upload their datasets to leverage K Pro’s AI reasoning and data analysis capabilities.
According to Thomas Clozel, MD, Co-founder and CEO of Owkin, K Pro represents a step towards achieving Biological Artificial Super Intelligence (BASI). K Pro has already accelerated internal drug target identification by 70% and built an IND-ready asset positioning strategy in hours instead of months.
K Pro builds upon Owkin’s approach to agentic AI biomedical discovery, validated through collaborations with companies including AstraZeneca, Bristol Myers Squibb and Sanofi. Ben Mellows, managing director at Micregen, used Owkin K to formulate his investor pitch and found that it delivered a clear story tailored to investors.
Owkin’s AI has delivered results for pharmaceutical clients, including preventing Phase 2 clinical trial futility, discovering new multimodal disease endotypes, and reducing trial duration. The company also partnered with STAT Brand Studio to survey over 200 pharma executives to ensure K Pro addresses real-world challenges.
Contact Information:
Alistair Jennings
Marketing Director: Content
alistair.jennings@owkin.com
+447983972126
Source: Owkin
